SynAct Pharma AB is a manufacturer of biological products. The Company is located in Lund, Sweden. It develops medicines for acute impairment in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.

Employees

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
18/06/26	10.96 kr	+2.81%	253,869
17/06/26	10.66 kr	-3.44%	797,845
16/06/26	11.04 kr	-8.76%	868,474
15/06/26	12.10 kr	-16.55%	3,933,065
12/06/26	14.50 kr	-0.28%	311,099

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe Europe Other stock markets 12:24:39 18/06/2026 BST			5-day change	1st Jan Change
11.03 ^SEK	+3.47%		-24.62%	-51.50%

06-17	Citadel Securities Europe emerges as new short seller in Synact Pharma	FW
06-15	SynAct Pharma AB - Special Call

Market Cap	567M 60.35M 52.06M 47.87M 45.05M 84.66M 5.7B 85.37M 221M 2.8B 227M 222M 9.67B	P/E 2026 *	-7.15x	P/E 2027 *	-14x
Enterprise Value	550M 58.49M 50.46M 46.39M 43.67M 82.05M 5.52B 82.74M 214M 2.71B 220M 215M 9.37B	EV / Sales 2026 *	3.96x	EV / Sales 2027 *	28x
Free-Float	70.28%	Yield 2026 *	-	Yield 2027 *	-

06-17	Citadel Securities Europe emerges as new short seller in Synact Pharma	FW
06-15	SynAct Pharma AB - Special Call
06-15	Peace Agreement Bolsters Stockholm Exchange, OMXS30 Index Gains 0.7 Percent	FW
06-15	Commodities and Industrials Show Strength on Stockholm Exchange, OMXS30 Index Gains 1.4 Percent	FW
06-15	Five stocks hit new 52-week lows on the Stockholm Stock Exchange today	FW
06-15	Stockholm Stock Exchange surges at the open, OMXS30 index gains 2.0 percent	FW
06-15	Synact Pharma Board and Management Enter Into Lock-Up Agreements	FW
06-15	Synact Pharma's resomelagon misses primary endpoint (Update)	FW
06-15	Synact Pharma reports positive Phase 2 results for rheumatoid arthritis treatment	FW
06-15	SynAct Pharma AB Reports Positive Results from Phase 2B Advance Study of Resomelagon in Rheumatoid Arthritis	CI
06-12	Peace Optimism Lifts Stockholm Exchange: Duni Falls on Profit Warning	FW
06-12	Synact secures US patent for resomelagon: exclusivity extended to 2044	FW
06-12	Synact Pharma Secures U.S. Patent	FW

03-04	Edison Raises Valuation of Synact Pharma - Commissioned Analysis	FW
02-09	Redeye Raises Target Price for Synact Pharma to 31 Kronor (26)	FW
31/10/25	Redeye Raises Target Price for Synact Pharma to 26 Kronor (25)	FW
28/10/25	Edison Initiates Coverage of Synact Pharma, Assigns Value of SEK 36.9 Per Share	FW
28/10/25	Edison Initiates Coverage of Synact Pharma, Assigns Value of SEK 36.9 per Share	FW

SynAct Pharma AB Share Price

Stocks

SYNACT

SE0008241491

Pharmaceuticals

Valuation: SynAct Pharma AB

Chart: SynAct Pharma AB

Latest news : SynAct Pharma AB

Last Transcript: SynAct Pharma AB

Analysts' recommendations: SynAct Pharma AB

Press Releases: SynAct Pharma AB

Quotes and Performance

Course Extremes

Managers and Directors: SynAct Pharma AB

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

06-16	SynAct Pharma: Updated Base Case after ADVANCE	AQ
06-15	SynAct Pharma (Interview): ADVANCE Topline Data	AQ
06-15	SynAct Pharma: 40mg Best Dose in ADVANCE	AQ
06-15	SynAct Pharma Board of Directors and Management Enter Lock-up Agreements	AQ
06-15	SynAct Pharma : Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis - supports phase 3 design, regulatory interactions, and partnering	PU

1 day	+3.47%
1 week	-24.62%
Current month	-37.08%
1 month	-22.38%
3 months	-36.72%
6 months	-47.56%
Current year	-51.50%

1 week	7.05	14.98
1 month	7.05	18.2
Current year	7.05	24.4
1 year	7.05	25.3
3 years	4.98	124.6
5 years	4.98	146
10 years	4.75	146

Manager	Title	Age	Since
Jeppe Øvlesen CEO	Chief Executive Officer	64	31/12/2013
Ann Kristin Led DFI	Director of Finance/CFO	-	28/02/2026
Kirsten Harting CTO	Chief Tech/Sci/R&D Officer	-	14/02/2024

Director	Title	Age	Since
Jeppe Øvlesen BRD	Director/Board Member	64	19/03/2024
Anders Kronborg CHM	Chairman	62	19/03/2024
Sten Scheibye BRD	Director/Board Member	74	19/03/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
03-09	Anders Kronborg	Buy	Chairman	2,750	0.0052%
03-08	Mads Bjerregaard	Buy	Executive/Senior Manager	1,500	0.0028%
03-08	Quantass ApS	Buy	Company	7,900	0.0148%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYNACT PHARMA AB	+3.47%	-24.62%	-31.50%	-85.23%	60.35M
ELI LILLY AND COMPANY	-0.94%	-2.14%	+40.54%	+148.38%	992B
JOHNSON & JOHNSON	-0.42%	-1.80%	+53.69%	+42.60%	564B
ABBVIE INC.	-0.56%	-1.65%	+19.27%	+59.57%	391B
ROCHE HOLDING AG	-1.06%	+0.68%	+24.66%	+16.53%	330B
ASTRAZENECA PLC	-0.65%	-1.44%	+26.87%	+14.91%	280B
NOVARTIS AG	-0.41%	-0.91%	+26.82%	+32.57%	279B
NOVO NORDISK A/S	-1.29%	-0.16%	-41.53%	-47.89%	196B
AMGEN INC.	-1.78%	+1.16%	+17.79%	+48.77%	184B
GILEAD SCIENCES, INC.	-1.40%	+3.27%	+16.16%	+59.08%	156B
Average	-0.30%	-1.90%	+15.28%	+28.93%	337.13B
Weighted average by Cap.	-0.48%	-0.49%	+29.30%	+65.83%

	2026 *	2027 *
Net sales	139M 14.76M 12.73M 11.71M 11.02M 20.71M 1.39B 20.88M 54.02M 684M 55.4M 54.22M 2.37B	21.15M 2.25M 1.94M 1.78M 1.68M 3.16M 212M 3.18M 8.23M 104M 8.45M 8.26M 361M
Net income	52.18M 5.55M 4.79M 4.4M 4.14M 7.79M 524M 7.85M 20.31M 257M 20.83M 20.39M 889M	-26.04M -2.77M -2.39M -2.2M -2.07M -3.89M -262M -3.92M -10.14M -128M -10.4M -10.18M -444M
Net Debt	-17.48M -1.86M -1.6M -1.48M -1.39M -2.61M -176M -2.63M -6.81M -86.14M -6.98M -6.83M -298M	24.86M 2.64M 2.28M 2.1M 1.97M 3.71M 250M 3.74M 9.68M 123M 9.93M 9.71M 424M